AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Altasciences

Published November 12, 2026 · Updated November 13, 2026

The Many Facets of Early Phase Evaluation of Psychedelics in Psychiatry - - Altasciences

Read the full story at Altasciences

Access Altasciences' comprehensive library of webinars and podcasts for the latest advancements in preclinical and clinical drug development.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics